CN113777309A - Application of autoantibody in preparation of pancreatic ductal adenocarcinoma diagnostic kit - Google Patents
Application of autoantibody in preparation of pancreatic ductal adenocarcinoma diagnostic kit Download PDFInfo
- Publication number
- CN113777309A CN113777309A CN202111042493.1A CN202111042493A CN113777309A CN 113777309 A CN113777309 A CN 113777309A CN 202111042493 A CN202111042493 A CN 202111042493A CN 113777309 A CN113777309 A CN 113777309A
- Authority
- CN
- China
- Prior art keywords
- ductal adenocarcinoma
- autoantibodies
- pancreatic ductal
- diagnostic kit
- izumo4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 title claims abstract description 42
- 238000009007 Diagnostic Kit Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 3
- 210000002966 serum Anatomy 0.000 claims description 17
- 239000000523 sample Substances 0.000 claims description 13
- 102100023568 ATP synthase F(0) complex subunit C1, mitochondrial Human genes 0.000 claims description 12
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims description 12
- 102100040624 Dehydrogenase/reductase SDR family member 7C Human genes 0.000 claims description 12
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 12
- 101000905799 Homo sapiens ATP synthase F(0) complex subunit C1, mitochondrial Proteins 0.000 claims description 12
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims description 12
- 101000817019 Homo sapiens Dehydrogenase/reductase SDR family member 7C Proteins 0.000 claims description 12
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 12
- 101001078207 Homo sapiens Izumo sperm-egg fusion protein 4 Proteins 0.000 claims description 12
- 101000821449 Homo sapiens Secreted and transmembrane protein 1 Proteins 0.000 claims description 12
- 102100025317 Izumo sperm-egg fusion protein 4 Human genes 0.000 claims description 12
- 102100021853 Secreted and transmembrane protein 1 Human genes 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 101001065832 Homo sapiens Low-density lipoprotein receptor class A domain-containing protein 4 Proteins 0.000 claims description 11
- 102100032094 Low-density lipoprotein receptor class A domain-containing protein 4 Human genes 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 101000794187 Homo sapiens Tetraspanin-18 Proteins 0.000 claims description 8
- 102100030175 Tetraspanin-18 Human genes 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 6
- 102100021392 Cationic amino acid transporter 4 Human genes 0.000 claims description 3
- 102100032280 Metal cation symporter ZIP14 Human genes 0.000 claims description 3
- 108091006944 SLC39A14 Proteins 0.000 claims description 3
- 108091006233 SLC7A4 Proteins 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 2
- 230000004520 agglutination Effects 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000003119 immunoblot Methods 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 18
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 20
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 19
- 201000002528 pancreatic cancer Diseases 0.000 description 19
- 208000008443 pancreatic carcinoma Diseases 0.000 description 19
- 230000035945 sensitivity Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000003745 diagnosis Methods 0.000 description 14
- 206010033645 Pancreatitis Diseases 0.000 description 13
- 238000012216 screening Methods 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- INZOTETZQBPBCE-NYLDSJSYSA-N 3-sialyl lewis Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@H](O)CO)[C@@H]([C@@H](NC(C)=O)C=O)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 INZOTETZQBPBCE-NYLDSJSYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 4
- 206010033649 Pancreatitis chronic Diseases 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 101000599778 Homo sapiens Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 description 1
- 101000988591 Homo sapiens Minor histocompatibility antigen H13 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102100029083 Minor histocompatibility antigen H13 Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
Abstract
The invention relates to the technical field of medical biological detection, and provides 10 autoantibodies: the invention further provides a kit for diagnosing pancreatic ductal adenocarcinoma by detecting the 10 autoantibodies. The kit and the detection method are simple, convenient, reliable, short in period, high in specificity and easy to popularize clinically.
Description
Technical Field
The invention relates to the technical field of medical biological detection, and relates to application of 10 autoantibodies in diagnosis of pancreatic ductal adenocarcinoma.
Background
The Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most common malignant tumors in China, about 90 percent of Pancreatic cancers are ductal adenocarcinoma originated from glandular epithelium, and the Pancreatic ductal adenocarcinoma has the characteristics of high morbidity, difficult early diagnosis, early recurrence and metastasis, poor prognosis and the like, and the 5-year survival rate is only 9 percent[1,2]. Surgical resection is the first choice and the only curative method for early-stage PDAC, but about 85 percent of PDAC diagnosis belongs to local advanced stage or is accompanied by distant metastasis, and surgical resection cannot be carried out, and chemotherapy is the main treatment measure for the part of patients, but is easy to resist drugs and poor in curative effect[3]. Therefore, the search for a diagnostic marker with high sensitivity and high specificity and the improvement of the early diagnosis rate still remain the problems to be solved urgently at present.
CA19-9 is a PDAC diagnostic marker which is widely used at present. The results of the series of studies showed that the median sensitivity and specificity of CA19-9 diagnostic PDAC were 79% and 82%, respectively[4,5]. The sensitivity of the PDAC with the tumor size less than or equal to 2cm diagnosed by CA19-9 is worse and is only 48.4 percent[6]. In addition, the increase of CA19-9 is also commonly seen in biliary tract malignant tumor, pancreatitis, jaundice, etc., and false positive appears, and over 15% of PDACs appear false negative due to Lewis antigen negative, etc[7-8]. There is therefore a need to combine or find new diagnostic markers.
The tumor immune microenvironment is one of ten characteristics of tumors, and the immune system of the body can generate autoantibodies against tumor antigens when recognizing the tumor as a 'foreign body'. When the tumor antigen level is very low and cannot be detected by using a conventional protein detection method, the immune system can monitor the existence of the protein, initiate immune reaction, generate a large amount of antibodies and play a certain amplification role in antigen signals. Therefore, the detection of the autoantibody is more sensitive than the tumor antigen, and a new way for early diagnosis of the tumor is possibly opened. It was found that several autoantibodies (e.g., anti-Ezrin, p53, p16, p62, survivin, Koc, IMP1, etc.) were involved in the development of PDAC[9-10]However, there is no systematic study on the sensitivity and specificity of these autoantibodies and their combinations for PDAC diagnosis, and there is no high throughput screening study on PDAC-related autoantibodies.
Disclosure of Invention
The present invention is made to solve the above technical problems, and an object of the present invention is to provide a diagnostic marker for pancreatic cancer, particularly ductal pancreatic adenocarcinoma, and an object of the present invention is to provide a novel use of antibodies against TSPAN18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39a14, SLC7a4, and LDLRAD4, that is, an application in the preparation of a ductal pancreatic adenocarcinoma diagnostic kit.
The 10 autoantibodies of the invention adopt HuProtTMScreening of human proteome chip, HuprotTMThe human proteome chip was originally developed by john hopkins university in usa, and through continuous upgrade, currently contains more than 20000 personal recombinant proteins, and is the highest-throughput human recombinant proteome chip so far. We are the first timeThis high throughput protein chip was used for the diagnosis of PDAC.
A preliminary screening was performed, and serum samples were collected from 30 PDAC patients and 30 healthy persons, each sample being tested using 1 HuProtTM protein chip and analyzed using the same standard as follows: for each protein, Fold Change (FC) (PDAC group mean/healthy group mean) and P value (t-test) were calculated, and autoantibodies meeting the conditions <0.05, FC >1.2 were selected, and a total of 165 were selected, wherein the type of response antibody was 83 IgG and the type of response antibody was 82 IgM.
Then, screening is carried out continuously, a pancreatic cancer exclusive chip containing the 165 proteins is customized, and detection verification is carried out on 266 cases of PDACs, 248 cases of healthy people and 98 cases of patients with pancreatitis. Screening out the autoantibodies meeting the conditions that FC is greater than 1.2 and P value is less than 0.05; the positive rate is more than 10%; the ROC curve is AUC >0.7, specificity > 70% and sensitivity > 70%. The total number of antibodies satisfying the above conditions is 10, and all antibodies are IgG antibodies: the 10 autoantibodies can be used as serum markers for pancreatic cancer diagnosis, namely anti-TSPAN 18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39A14, SLC7A4 and LDLRAD4 antibodies.
In a first aspect of the present invention, there is provided an application of an autoantibody in preparing a pancreatic ductal adenocarcinoma diagnostic reagent or a diagnostic kit, wherein the autoantibody is any one or a combination of antibodies against TSPAN18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39a14, SLC7a4, and LDLRAD 4.
Preferably, the diagnostic reagent is a reagent for detecting the content of antibodies against TSPAN18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39a14, SLC7a4 and LDLRAD4 in a biological serum sample.
Preferably, the diagnostic kit comprises reagents for detecting the content of antibodies against TSPAN18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39a14, SLC7a4, LDLRAD4 in a biological serum sample.
Preferably, the biological sample is obtained from peripheral blood of the subject and the serum sample is obtained by centrifugation after blood sample collection.
In the invention, the content or concentration of the antibody is detected by adopting a conventional method, such as a traditional precipitation test, an agglutination test, a complement fixation test and the like, and the enzyme-linked immunosorbent assay, the fluorescence immunity, the radioimmunoassay or the immunoblotting method which are developed in recent years are all suitable.
In a second aspect of the present invention, a pancreatic ductal adenocarcinoma diagnostic kit is provided, which comprises reagents for detecting the content of antibodies against TSPAN18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39a14, SLC7a4, and LDLRAD4 in a biological serum sample, that is, related reagents corresponding to the detection method are included.
In a third aspect of the present invention, there is provided a method for diagnosing pancreatic ductal adenocarcinoma using the above-mentioned kit, comprising:
A. centrifuging a blood sample to be detected at normal temperature to obtain serum;
B. the levels of the above 10 autoantibodies in serum were detected by a conventional method of antibody detection, and whether pancreatic ductal adenocarcinoma was detected or not was judged based on the detection results.
After pairwise comparison between groups by using an LSD method, the pancreatic ductal adenocarcinoma is found to have significant difference in expression level with the chronic pancreatitis and the normal human antibody respectively. The ROC analysis result indicates that when the kit is used for distinguishing pancreatic ductal adenocarcinoma, chronic pancreatitis and a mixture of normal people, the area under AUC is higher than 0.75, and the specificity and the sensitivity are higher than 70%; when the method is used for distinguishing pancreatic ductal adenocarcinoma from chronic pancreatitis, the area under AUC is higher than 0.82, the diagnosis accuracy is higher, and the false positive rate of cancer screening is reduced.
The invention has the following beneficial guarantee and effects:
in terms of technology, the detection of 10 kinds of autoantibodies is essentially the detection of antibody levels or concentrations in serum samples, and the clinical detection method is mature, has the characteristics of simple and convenient operation, sensitive detection, good specificity, high repeatability and the like, and is high in clinical popularization.
In addition, the area under AUC of the 10 autoantibody indexes related by the invention is higher than 0.75, the diagnosis accuracy is at least moderate, the sensitivity of most antibodies is maintained above 71%, the specificity is as high as above 80%, compared with CA19-9, the clinical reference value and the reliability are higher, and compared with pathological section diagnosis, the pain and the harm of a detector are small. Therefore, the detection kit can improve the detection rate and accuracy of the pancreatic ductal adenocarcinoma, and can obtain a detection result only by collecting blood of a detector, so that the compliance of a patient is high.
The invention provides a pancreatic ductal adenocarcinoma assay kit based on antibody level assay, which can diagnose pancreatic cancer by detecting the antibody level in a patient serum sample, has simple and convenient assay method, short period and high sensitivity, and is an effective supplement of the existing assay method.
Drawings
FIG. 1 is HuprotTMA detection schematic diagram of a human proteome chip;
FIG. 2 is a flow chart of the screening of 10 autoantibodies according to the present invention;
FIG. 3 is a ROC curve for diagnosing pancreatic cancer using 10 autoantibodies of the present invention: A. pancreatic cancer vs (healthy + pancreatitis), b. pancreatic cancer vs healthy person, c. pancreatic cancer vs pancreatitis;
FIG. 4 shows the expression level differences of 10 autoantibodies of the present invention in pancreatic cancer, pancreatitis and serum of healthy persons (. about.P <0.05,. about.P <0.01,. about.P <0.001,. about.P <0.0001, ns no statistical difference)
FIG. 5 is a ROC curve of 10 autoantibodies of the invention diagnosing CA199 negative pancreatic cancer: A.CA199-pancreatic cancer vs. (healthy + pancreatitis), B.CA199-pancreatic cancer vs healthy human, C.CA199-pancreatic cancer vs pancreatitis.
Detailed Description
The present invention will now be described in detail with reference to examples and drawings, but the practice of the invention is not limited thereto.
EXAMPLE one Ten autoantibodies screening and validation
The screening and verification process in this embodiment is shown in fig. 2, and specifically includes the following steps:
1. preliminary screening stage
Serum samples were collected from 30 PDAC patients and 30 healthy persons, and each sample was examined using 1 HuProtTM protein chip according to the following detection principle, as shown in FIG. 1: the specific antibody (including IgG, IgM or other antibodies) of the chip is combined with the protein fixed on the chip, the unbound antibody and other proteins are removed by cleaning, then the anti-human IgM fluorescent labeled secondary antibody (cy5 labeled and shown in red) and the anti-human IgG fluorescent secondary antibody (cy3 labeled and shown in green) are used for detection, the signal is read by a fluorescence scanner, and the strength of the signal is positively correlated with the affinity and the quantity of the antibody. And extracting and normalizing the data, and analyzing the data.
IgG and IgM data were integrated and analyzed on the same standard as follows: for each protein, Fold Change (FC) (PDAC group mean/healthy group mean) and P value (t-test) were calculated, and autoantibodies meeting the conditions <0.05, FC >1.2 were selected, and a total of 165 were selected, wherein the type of response antibody was 83 IgG and the type of response antibody was 82 IgM.
2. Verification phase
A pancreatic cancer-specific chip containing 165 proteins was prepared, and the detection was performed in 266 cases of PDACs, 248 cases of healthy persons, and 98 cases of pancreatitis patients. And extracting and normalizing the data, and analyzing the data.
IgG and IgM data were integrated and analyzed on the same standard as follows: for each protein, Fold Change (FC) (PDAC group mean/healthy + pancreatitis group mean), P value (t test), and positive rate were calculated, i.e., the frequency of autoantibodies appearing in each group of samples was counted under a certain threshold. Firstly, setting a threshold value for the response of each protein, namely the average value of a control group sample of the protein +2 SD; secondly, samples above this threshold are defined as autoantibody positive), ROC curve (AUC, sensitivity, specificity).
Screening out the autoantibodies meeting the conditions that FC is greater than 1.2 and P value is less than 0.05; the positive rate is more than 10%; the ROC curve is AUC >0.7, specificity > 70% and sensitivity > 70%. The total number of the proteins meeting the above conditions is 10, and all the proteins are IgG antibodies: anti-TSPAN 18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39a14, SLC7a4, LDLRAD4 antibodies. The 10 autoantibodies can be used as serum markers for early diagnosis of pancreatic cancer.
10 autoantibodies screened according to the above procedure: anti-TSPAN 18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39a14, SLC7a4, LDLRAD4 antibodies, AUC, sensitivity, specificity for PDAC diagnosis as shown in table 1 below, ROC curves for 10 autoantibodies to PDAC diagnosis are shown in fig. 3.
Table 110 summary of cut-off, sensitivity, specificity, positive predictive value, negative predictive value for autoantibody diagnostic PDACs
The ROC analysis result indicates that the area under AUC of the PDAC vs. healthy human group is between 0.77 and 0.80, the diagnosis accuracy is moderate, the specificity result is between 66 and 82 percent, and the sensitivity is between 62 and 78 percent; in the PDAC vs. pancreatitis group, the area under AUC is between 0.82 and 0.89, the specificity result is between 72 and 89 percent, the sensitivity is between 64 and 80 percent, and PDAC patients can be effectively distinguished from healthy people and pancreatitis patients.
According to fig. 4, the LSD method was used to compare two-by-two groups, and 10 autoantibodies were found to be significantly higher in serum of patients with pancreatic ductal adenocarcinoma than those of chronic pancreatitis and healthy persons (P <0.001), and it was preliminarily determined that 10 autoantibodies could be used as a diagnosis of pancreatic cancer.
3. Diagnostic efficacy in CA 199-negative pancreatic cancer patients
CA199 is a widely used pancreatic cancer diagnostic marker at present, and the diagnostic efficacy of these 10 autoantibodies in CA 199-negative pancreatic cancer patients was further analyzed.
Table 210 Critical values, sensitivity, specificity, Positive predictive value, negative predictive value summary of autoantibody diagnosis CA199 negative PDACs
According to the ROC analysis result of FIG. 5, the area under AUC of the CA199 negative PDAC vs. healthy group is between 0.70 and 0.78, the diagnosis accuracy is moderate, the specificity result is between 65% and 83%, and the sensitivity is between 58% and 79%; in the CA199 negative PDAC vs. pancreatitis group, the area under AUC is between 0.77 and 0.86, the specificity result is between 72 and 90 percent, the sensitivity is between 67 and 79 percent, and CA199 negative PDAC patients can be effectively distinguished from healthy people and pancreatitis patients.
Reference documents:
[1]Siegel RL,Miller KD,Fuchs HE,et al.Cancer Statistics,2021.CA:a cancer journal for clinicians 2021；71.
[2]McGuigan A,Kelly P,Turkington RC,et al.Pancreatic cancer:A review of clinical diagnosis,epidemiology,treatment and outcomes.World journal of gastroenterology 2018；24:4846-4861.
[3]Chari ST,Kelly K,Hollingsworth MA,et al.Early detection of sporadic pancreatic cancer:summative review.Pancreas 2015；44:693-712.
[4]Goonetilleke KS,Siriwardena AK.Systematic review of carbohydrate antigen(CA 19-9)as a biochemical marker in the diagnosis of pancreatic cancer,European journal of surgical oncology 2007；33:266-270.
[5]Luo G,Jin K,Deng S,et al.Roles of CA19-9 in pancreatic cancer:Biomarker,predictor andpromoter.Biochim Biophys Acta Rev Cancer.2021；1875(2):188409.
[6]Egawa S,Takeda K,Fukuyama S,et al.Clinicopathological aspects ofsmall pancreatic cancer.Pancreas 2004；28(3):235–40.
[7]Mann DV,Edwards R,Ho S,et al.Elevated tumour marker CA19-9:clinical interpretation and influence of obstructive jaundice.European journal of surgical oncology 2000；26:474-479.
[8]Kim JE,Lee KT,Lee JK,et al.Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.Journal of gastroenterology and hepatology 2004；19:182-186.
[9]Capello M,Cappello P,Linty FC,et al.Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.Journal of hematology&oncology 2013；6:67.
[10]Li J,Wang LJ,Ying X,et al.Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer.Scandinavian journal ofimmunology 2012；75:342-349.
while the preferred embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that the invention is not limited thereto, and that various changes and modifications may be made without departing from the spirit of the invention, and the scope of the appended claims is to be accorded the full scope of the invention.
Claims (6)
1. The application of the autoantibody in preparing a pancreatic ductal adenocarcinoma diagnostic reagent or a diagnostic kit is characterized in that any one or more of anti-TSPAN 18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39A14, SLC7A4 and LDLRAD4 antibodies are combined.
2. The use of claim 1, wherein the diagnostic reagent is a reagent for detecting the levels of antibodies against TSPAN18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39a14, SLC7a4, LDLRAD4 in a biological serum sample.
3. The use of claim 1, wherein the diagnostic kit comprises reagents for detecting the level of antibodies against TSPAN18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39a14, SLC7a4, LDLRAD4 in a biological serum sample.
4. The use of claim 2 or 3, wherein the biological sample is obtained from peripheral blood of the subject.
5. A pancreatic ductal adenocarcinoma diagnostic kit comprises reagents for detecting the content of antibodies against TSPAN18, ENTPD1, IZUMO4, DHRS7C, ATP5G1, SECTM1, CPT1A, SLC39A14, SLC7A4 and LDLRAD4 in a biological serum sample.
6. The pancreatic ductal adenocarcinoma diagnostic kit according to claim 5, characterized in that:
wherein, the reagent is detected by adopting a precipitation test, an agglutination test, a complement fixation test, enzyme-linked immunosorbent assay, fluorescence immunization, radioimmunoassay or an immunoblotting method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111042493.1A CN113777309A (en) | 2021-09-07 | 2021-09-07 | Application of autoantibody in preparation of pancreatic ductal adenocarcinoma diagnostic kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111042493.1A CN113777309A (en) | 2021-09-07 | 2021-09-07 | Application of autoantibody in preparation of pancreatic ductal adenocarcinoma diagnostic kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113777309A true CN113777309A (en) | 2021-12-10 |
Family
ID=78841418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111042493.1A Pending CN113777309A (en) | 2021-09-07 | 2021-09-07 | Application of autoantibody in preparation of pancreatic ductal adenocarcinoma diagnostic kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113777309A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040219540A1 (en) * | 2001-01-17 | 2004-11-04 | Manfred Nilius | Method for detecting pancreatic and gastro-intestinal illnesses |
| WO2006110593A2 (en) * | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| US20150177249A1 (en) * | 2012-06-15 | 2015-06-25 | Natimab Therapeutics S.R.L. | Method and a kit for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma |
| JP5852759B1 (en) * | 2015-04-01 | 2016-02-03 | 株式会社キュービクス | Detection of pancreatic cancer by gene expression analysis |
| US20160041153A1 (en) * | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
| CN106290888A (en) * | 2016-08-04 | 2017-01-04 | 韩晓 | The antibody compositions of detection ductal adenocarcinoma of pancreas immunohistochemical markers protein combination and application thereof |
| CN110121647A (en) * | 2016-12-15 | 2019-08-13 | 得克萨斯大学体系董事会 | Method for detecting and treating ductal adenocarcinoma of pancreas |
| WO2019178269A2 (en) * | 2018-03-14 | 2019-09-19 | Surface Oncology, Inc. | Antibodies that bind cd39 and uses thereof |
| CN110787296A (en) * | 2018-08-01 | 2020-02-14 | 复旦大学附属肿瘤医院 | Pharmaceutical composition for preventing or treating pancreatic cancer and kit for detecting pancreatic cancer |
| CN111562395A (en) * | 2020-06-11 | 2020-08-21 | 青岛大学 | Marker of pancreatic cancer tumor and application and kit thereof |
-
2021
- 2021-09-07 CN CN202111042493.1A patent/CN113777309A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040219540A1 (en) * | 2001-01-17 | 2004-11-04 | Manfred Nilius | Method for detecting pancreatic and gastro-intestinal illnesses |
| WO2006110593A2 (en) * | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| US20160041153A1 (en) * | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
| US20150177249A1 (en) * | 2012-06-15 | 2015-06-25 | Natimab Therapeutics S.R.L. | Method and a kit for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma |
| JP5852759B1 (en) * | 2015-04-01 | 2016-02-03 | 株式会社キュービクス | Detection of pancreatic cancer by gene expression analysis |
| CN106290888A (en) * | 2016-08-04 | 2017-01-04 | 韩晓 | The antibody compositions of detection ductal adenocarcinoma of pancreas immunohistochemical markers protein combination and application thereof |
| CN110121647A (en) * | 2016-12-15 | 2019-08-13 | 得克萨斯大学体系董事会 | Method for detecting and treating ductal adenocarcinoma of pancreas |
| WO2019178269A2 (en) * | 2018-03-14 | 2019-09-19 | Surface Oncology, Inc. | Antibodies that bind cd39 and uses thereof |
| CN110787296A (en) * | 2018-08-01 | 2020-02-14 | 复旦大学附属肿瘤医院 | Pharmaceutical composition for preventing or treating pancreatic cancer and kit for detecting pancreatic cancer |
| CN111562395A (en) * | 2020-06-11 | 2020-08-21 | 青岛大学 | Marker of pancreatic cancer tumor and application and kit thereof |
Non-Patent Citations (2)
| Title |
|---|
| AHMAD RUSHDI SHAKRI等: "upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia", 《CANCERS》, vol. 12, no. 3, pages 1 - 17 * |
| 胡强等: "蛋白质组学技术在胰腺癌标志物中的研究进展", 《中国现代医学杂志》, vol. 18, no. 16, pages 2348 - 2352 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6220919B2 (en) | Methods and marker combinations for screening for propensity to lung cancer | |
| Lopez | Recent developments in the first detection of hepatocellular carcinoma | |
| JP5256284B2 (en) | Serum biomarkers for early detection of lung cancer | |
| Bienvenu et al. | Evaluation of a point-of-care test based on deamidated gliadin peptides for celiac disease screening in a large pediatric population | |
| CN106680503B (en) | The screening and identification method and its application of a kind of ECH1 autoantibodies | |
| CN112379096B (en) | Application of exosome membrane protein as colon cancer diagnosis marker and colon cancer early diagnosis kit | |
| CN104515797A (en) | Breast cancer early stage diagnosis sialoprotein fingerprint model and construction method thereof | |
| CN105092845A (en) | Pancreatic cancer protein biomarker and application and detection chip thereof, and detection device | |
| CN109142729A (en) | A kind of anti-HMGB3 autoantibody of lung cancer marker and its application | |
| CN109470859A (en) | A kind of excretion body protein is as identifying the good pernicious marker of Lung neoplasm and its application | |
| EP3631453A1 (en) | Novel stool-based protein biomarkers for colorectal cancer screening | |
| CN108646032A (en) | Purposes of the TOP2A autoantibodies as pulmonary cancer diagnosis marker | |
| Maleki et al. | Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease | |
| CN108548923B (en) | Reagent kit for diagnosing early specific autoantibody panel of small cell lung carcinoma | |
| Xu et al. | Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer | |
| CN113862353A (en) | M of total RNA of peripheral blood immune cells6Application of detection reagent for A modification level in preparation of colorectal cancer diagnosis product | |
| CN109116023B (en) | Lung cancer marker anti-MMP 12 autoantibody and application thereof | |
| CN109975548B (en) | Application of IgG4 detection reagent in preparation of colorectal cancer diagnostic agent | |
| CN109142730B (en) | Lung cancer marker anti-PSIP 1 autoantibody and application thereof | |
| CN113777309A (en) | Application of autoantibody in preparation of pancreatic ductal adenocarcinoma diagnostic kit | |
| Xiu et al. | Diagnostic value of the survivin autoantibody in four types of malignancies | |
| CN114724707A (en) | Hepatocellular carcinoma autoantibody marker combined diagnosis model | |
| Trulson et al. | Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations | |
| CN108333375B (en) | Reagent kit for diagnosing lung non-small cell cancer early stage specific autoantibody panel | |
| CN1547030A (en) | Colorectal cancer early diagnosis utilizing serological specificity protein group finger print |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211210 |